Je­re­my Levin joins the biotech IPO rush, gain­ing $75M for Ovid’s R&D game plan

Je­re­my Levin is once again run­ning a pub­lic com­pa­ny. His start­up Ovid Ther­a­peu­tics $OVID has suc­cess­ful­ly launched an IPO, rais­ing $75 mil­lion af­ter sell­ing 5 mil­lion shares at $15 each — the low end of the range.

The move came as Uro­gen saw its shares $URGN climb north af­ter rais­ing $58 mil­lion in an up­sized IPO. But the fi­nan­cial prize of the day went to Bio­haven $BHVN, which snagged $168 mil­lion af­ter sell­ing 9.9 mil­lion shares. Add it all up and you’re look­ing at the first sol­id ev­i­dence that the IPO win­dow is widen­ing, with more such plays in the off­ing as some pa­tient com­pa­nies that have been bid­ing their time start to jump in on the ac­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER